

## Disclosures

### Personal Commercial (2)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
Faraday Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	Acute Coronary Syndromes
Xenter	Other - Stock options	None (\$0)	Invasive CV Angio and Interventions

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (3)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
American College of Cardiology	Other - Co-Editor Cath SAP	Significant (>= \$5,000)	
American Heart Association	Other - Senior Guest Editor, Circulation Intervention	Significant (>= \$5,000)	Invasive CV Angio and Interventions
SCAI	Other - On SCAI Education Council	None (\$0)	

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (5)

Year	Case Title	Represented	Description	Compensation
<b>Self</b>				
2024	Negligence	Defendant		Modest (< \$5,000)
2016	Delay in treatment	Defendant	Patient with acute stent thrombosis	Modest (< \$5,000)
2016	Failure to prescribe	Defendant	Stent thrombosis in patient who failed to fill prescription for DAPT	Modest (< \$5,000)
2015	Negligence	Defendant	Allegation of failure to provide timely revascularization in a STEMI patient with spontaneous coronary artery dissection	Significant (>= \$5,000)
2013	Malpractice	Defendant	Issue of failure to diagnose	Modest (< \$5,000)

† Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 8/28/2025

 URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

### Confidentiality, Disclosure and Assignment Agreement | Signed on 8/28/2025

 URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

### Embargo | Signed on 8/28/2025

 URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

### On-Going Obligation Agreement | Signed on 8/28/2025

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.